Treatment Options for Early-Stage HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.

Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.

An expert oncologist explains the combination subcutaneous injection therapy of pertuzumab, trastuzumab, and hyaluronidase-zzxf for patients with early-stage HER2+ breast cancer.

Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.

A key opinion leader explains how she discusses treatment options and trial data with patients with early stage HER2+ breast cancer.

Dr Sarah M. Tolaney discusses whether maintenance therapy has a role in HER2+ breast cancer treatment.

Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.